Idiopathic Pulmonary Fibrosis

Cost-Effectiveness of Nintedanib in Idiopathic Pulmonary Fibrosis in the U.S.

Presented at AMCP NEXUS. October 22-25, 2018. Orlando, USA


Rinciog C, Bermingham S, Cornic L, Diamantopoulos A, Fan Y 



Qualitative and quantitative summary of burden of disease compared with healthy population

Publications in other disease areas

Atrial fibrillation

Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke


Societal costs of Er+/Her2- advanced or metastatic breast cancer in post-menopausal women in the United Kingdom

Idiopathic pulmonary fibrosis

The burden of illness of idiopathic pulmonary fibrosis: a comprehensive evidence review


The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis

Rheumatoid arthritis

Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK


Venous thromboembolism

Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective